Pentapeptide Arg-Trp-Arg-Asn-Met Targets Integrin Alpha V Beta 3
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly chemotherapy, lack specificity for tumor cells, leading to organ toxicities, and existing integrin-targeting therapies are not as effective for tumors expressing high levels of the integrin receptor αvβ3.
Innovation Solution
A pentapeptide with the sequence Arg-Trp-Arg-Asn-Met is developed, which exhibits high affinity for the integrin receptor αvβ3, allowing for targeted tumor diagnostics and therapy, particularly for glioma, breast cancer, melanoma, prostate cancer, and ovarian cancer, with low cytotoxicity and high specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional chemotherapeutic agents are used for cancer treatment, then cancer cells can be killed, but organ toxicities occur due to lack of specificity
Solution Approach 1:
The patent applies local quality by designing a pentapeptide with specific amino acid sequence (Arg-Trp-Arg-Asn-Met) that exhibits high affinity specifically for integrin αvβ3 receptors overexpressed on tumor cells. This localized specificity allows the peptide to selectively bind to and accumulate in tumor tissues while sparing normal organs, thereby maintaining therapeutic efficacy while reducing systemic organ toxicities associated with traditional chemotherapeutic agents.
2Reliability
If tripeptide is used to target integrin αvβ3, then some tumor targeting is achieved, but affinity and effectiveness are insufficient
Solution Approach 1:
The patent applies composite materials by constructing a pentapeptide that combines the known active tripeptide sequence (Arg-Trp-Arg) with two additional amino acids (Asn-Met). This composite structure leverages the proven integrin-binding capability of the RWR motif while the appended Asn-Met residues enhance overall affinity and stability. The synergistic effect of this composite peptide structure results in significantly improved binding affinity and targeting effectiveness compared to the parent tripeptide alone.
3Reliability
If peptide length is increased from tripeptide to pentapeptide, then affinity for integrin αvβ3 is improved, but molecular complexity increases
Solution Approach 1:
The patent applies parameter changes by systematically varying the length and composition of the peptide chain. Starting from the known tripeptide sequence, the inventors extended it to a pentapeptide by adding two specific amino acid residues (Asn-Met). This controlled parameter change optimizes the balance between binding affinity and structural simplicity, achieving enhanced affinity for integrin αvβ3 while maintaining a relatively simple linear peptide structure that is still amenable to synthesis and pharmaceutical development.
Data Source
AI summary
A pentapeptide associated with integrin receptor αvβ3, which has a sequence of arginine-tryptophan-arginine-asparagine-methionine. The pentapeptide targets tumor cells highly expressing αvβ3, but not tumor cells lowly expressing αvβ3 and normal cells. Accordingly, the pentapeptide is useful in the diagnosis and treatment of cancers.